ARMP — Armata Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $96.34m
- $165.12m
- $4.53m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 21.27 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -54.64% | ||
| Return on Equity | -3439.35% | ||
| Operating Margin | -988.14% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 0.82 | 4.47 | 5.51 | 4.53 | 4.65 | 2.75 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. Th Company is engaged in developing and advancing a pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Its two lead candidates addresses both chronic and acute bacterial infections. The Company's first lead candidate focused primarily on chronic bacterial infections is the clinical phage candidate for Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.
Directors
- Brian Varnum CEO (61)
- Steven Martin CFO (60)
- Duane Morris VOP (71)
- Mina Pastagia VPR
- Todd Patrick DRC (57)
- Jules Haimovitz IND (70)
- Odysseas Kostas IND (46)
- Robin Kramer IND (55)
- Joseph Patti IND (56)
- Todd Peterson IND (63)
- Sarah Schlesinger IND (61)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 9th, 1989
- Public Since
- May 20th, 1994
- No. of Shareholders
- 73
- No. of Employees
- 66
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NYSE MKT
- Shares in Issue
- 36,148,539
- Address
- 5005 Mcconnell Ave, LOS ANGELES, 90066
- Web
- https://www.armatapharma.com/
- Phone
- +1 3106652928
- Contact
- Joyce Allaire
- Auditors
- Ernst & Young LLP
Upcoming Events for ARMP
Armata Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2024 Armata Pharmaceuticals Inc Earnings Release
Armata Pharmaceuticals Inc Annual Shareholders Meeting
Similar to ARMP
Actinium Pharmaceuticals
NYSE MKT
Aeon Biopharma
NYSE MKT
AIM ImmunoTech
NYSE MKT
Azitra
NYSE MKT
Biomx
NYSE MKT
FAQ
What is the Armata Pharmaceuticals share price?
As of Today at 19:02 UTC, shares in Armata Pharmaceuticals are trading at $2.67. This share price information is delayed by 15 minutes.
How has the Armata Pharmaceuticals share price performed this year?
Shares in Armata Pharmaceuticals last closed at $2.67 and the price had moved by +64.61% over the past 365 days. In terms of relative price strength the Armata Pharmaceuticals share price has outperformed the S&P500 Index by +36.98% over the past year.
What are the analyst and broker recommendations for Armata Pharmaceuticals?
The overall consensus recommendation for Armata Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Armata Pharmaceuticals dividend yield?
Armata Pharmaceuticals does not currently pay a dividend.
Does Armata Pharmaceuticals pay a dividend?
Armata Pharmaceuticals does not currently pay a dividend.
When does Armata Pharmaceuticals next pay dividends?
Armata Pharmaceuticals does not currently pay a dividend.
How do I buy Armata Pharmaceuticals shares?
To buy shares in Armata Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Armata Pharmaceuticals?
As of the previous close price of $2.67, shares in Armata Pharmaceuticals had a market capitalisation of $96.34m.
Where are Armata Pharmaceuticals shares listed?
Here are the trading details for Armata Pharmaceuticals:
- Country of listing: United States
- Exchange: ASQ
- Ticker Symbol: ARMP
What kind of share is Armata Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Armata Pharmaceuticals is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Armata Pharmaceuticals share price forecast for 2024?
The analyst consensus target price for shares in Armata Pharmaceuticals is $8.00. That is 200.19% above the last closing price of $2.67.
Analysts covering Armata Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$1.34 for the next financial year.
What is the trend in the Armata Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Armata Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +14.27%.
As of the last closing price of $2.67, shares in Armata Pharmaceuticals were trading -9.08% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Armata Pharmaceuticals PE Ratio?
The Armata Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.67.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Armata Pharmaceuticals?
Armata Pharmaceuticals' management team is headed by:
- Brian Varnum - CEO
- Steven Martin - CFO
- Duane Morris - VOP
- Mina Pastagia - VPR
- Todd Patrick - DRC
- Jules Haimovitz - IND
- Odysseas Kostas - IND
- Robin Kramer - IND
- Joseph Patti - IND
- Todd Peterson - IND
- Sarah Schlesinger - IND